Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
J Neurosci ; 28(43): 10875-84, 2008 Oct 22.
Artigo em Inglês | MEDLINE | ID: mdl-18945895

RESUMO

Wnt/wingless signaling contributes to the development of neuronal synapses, including the Drosophila neuromuscular junction. Loss of wg (wingless) function alters the number and structure of boutons at this model synapse. Examining Wnt/wingless signaling mechanisms, we find that a distinct pathway operates presynaptically in the motoneuron and can account for many of the effects of wingless at this synapse. This pathway includes the canonical elements arrow/LRP (low-density lipoprotein receptor-related protein), dishevelled, and the glycogen synthase kinase shaggy (GSK3) and regulates the formation of microtubule loops within synaptic boutons as well as the number of synaptic boutons. This pathway, however, appears to be independent of beta-catenin signaling and the transcriptional regulation that is most frequently downstream of these components. Instead, inhibition of shaggy is likely to act locally. This pathway thus provides a parallel mechanism to the postsynaptic activation of frizzled receptors and indicates that synaptic development results from the bidirectional influence of wingless on both presynaptic and postsynaptic structures via distinct intracellular pathways.


Assuntos
Junção Neuromuscular/crescimento & desenvolvimento , Junção Neuromuscular/genética , Terminações Pré-Sinápticas/metabolismo , Transdução de Sinais/fisiologia , Proteínas Wnt/fisiologia , Animais , Animais Geneticamente Modificados , Drosophila , Proteínas de Drosophila/genética , Receptores Frizzled/genética , Receptores Frizzled/metabolismo , Proteínas de Fluorescência Verde/genética , Proteínas de Fluorescência Verde/metabolismo , Peroxidase do Rábano Silvestre/metabolismo
2.
J Exp Med ; 203(3): 513-8, 2006 Mar 20.
Artigo em Inglês | MEDLINE | ID: mdl-16533887

RESUMO

Formation of fibrin is critical for limiting blood loss at a site of blood vessel injury (hemostasis), but may also contribute to vascular thrombosis. Hereditary deficiency of factor XII (FXII), the protease that triggers the intrinsic pathway of coagulation in vitro, is not associated with spontaneous or excessive injury-related bleeding, indicating FXII is not required for hemostasis. We demonstrate that deficiency or inhibition of FXII protects mice from ischemic brain injury. After transient middle cerebral artery occlusion, the volume of infarcted brain in FXII-deficient and FXII inhibitor-treated mice was substantially less than in wild-type controls, without an increase in infarct-associated hemorrhage. Targeting FXII reduced fibrin formation in ischemic vessels, and reconstitution of FXII-deficient mice with human FXII restored fibrin deposition. Mice deficient in the FXII substrate factor XI were similarly protected from vessel-occluding fibrin formation, suggesting that FXII contributes to pathologic clotting through the intrinsic pathway. These data demonstrate that some processes involved in pathologic thrombus formation are distinct from those required for normal hemostasis. As FXII appears to be instrumental in pathologic fibrin formation but dispensable for hemostasis, FXII inhibition may offer a selective and safe strategy for preventing stroke and other thromboembolic diseases.


Assuntos
Isquemia Encefálica/metabolismo , Deficiência do Fator XII/metabolismo , Fator XII/metabolismo , Hemostasia , Trombose/metabolismo , Animais , Inibidores dos Fatores de Coagulação Sanguínea/administração & dosagem , Vasos Sanguíneos/metabolismo , Vasos Sanguíneos/patologia , Isquemia Encefálica/patologia , Isquemia Encefálica/prevenção & controle , Deficiência do Fator XI/tratamento farmacológico , Deficiência do Fator XI/metabolismo , Deficiência do Fator XI/patologia , Fator XII/antagonistas & inibidores , Deficiência do Fator XII/patologia , Feminino , Fibrina/metabolismo , Hemostasia/efeitos dos fármacos , Masculino , Camundongos , Camundongos Knockout , Trombose/tratamento farmacológico , Trombose/patologia
3.
Int Urogynecol J Pelvic Floor Dysfunct ; 17(6): 586-92, 2006 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-16538422

RESUMO

The aim of this study was to define the concept of hypermobility of the bladder neck and determine its effects on the cure rate and postoperative complications in patients undergoing colposuspension. In a retrospective study, 310 patients who underwent primary colposuspension for urodynamically proven genuine stress urinary incontinence were assessed by introital ultrasound before surgery and during follow-up for up to 48 months postoperatively. A total of 152 women completed 48 months of follow-up. Mobility of the bladder neck during straining was described as linear dorsocaudal movement (LDM) with LDM >15 mm being defined as hypermobility. The overall objective cure rate was 90.0% at 6-month follow-up vs 76.8% at 48-month follow-up (Kaplan-Meier estimators). Urge symptoms occurred in 12.6% (39/310) of the women and de novo urge incontinence in 2.3% (7/310). Bladder neck hypermobility was significantly reduced after anti-incontinence surgery, from 67.1% (208/310) before surgery to 5.5% (17/310) immediately after surgery (P<0.0001). Postoperative hypermobility was associated with a higher recurrence rate. In the hypermobility group, 52.9 and 34.0% of the patients were continent for up to 6 and 48 months, respectively, as opposed to 92.2 and 79.2% in the group without hypermobility (P<0.0001). Women with postoperative hypermobility had a 3.2-fold higher risk of recurrence within 48 months. Bladder neck hypermobility after surgery was also associated with postoperative voiding difficulty (P=0.0278). Patients in whom hypermobility of the bladder neck diagnosed before surgery persists after colposuspension have a higher risk of recurrence and are more likely to develop postoperative complications than those without this hypermobility.


Assuntos
Uretra/fisiopatologia , Incontinência Urinária por Estresse/fisiopatologia , Incontinência Urinária por Estresse/cirurgia , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Pessoa de Meia-Idade , Período Pós-Operatório , Prognóstico , Ultrassonografia , Uretra/diagnóstico por imagem , Bexiga Urinária/diagnóstico por imagem , Incontinência Urinária por Estresse/diagnóstico por imagem
4.
J Exp Med ; 202(2): 271-81, 2005 Jul 18.
Artigo em Inglês | MEDLINE | ID: mdl-16009717

RESUMO

Blood coagulation is thought to be initiated by plasma protease factor VIIa in complex with the membrane protein tissue factor. In contrast, coagulation factor XII (FXII)-mediated fibrin formation is not believed to play an important role for coagulation in vivo. We used FXII-deficient mice to study the contributions of FXII to thrombus formation in vivo. Intravital fluorescence microscopy and blood flow measurements in three distinct arterial beds revealed a severe defect in the formation and stabilization of platelet-rich occlusive thrombi. Although FXII-deficient mice do not experience spontaneous or excessive injury-related bleeding, they are protected against collagen- and epinephrine-induced thromboembolism. Infusion of human FXII into FXII-null mice restored injury-induced thrombus formation. These unexpected findings change the long-standing concept that the FXII-induced intrinsic coagulation pathway is not important for clotting in vivo. The results establish FXII as essential for thrombus formation, and identify FXII as a novel target for antithrombotic therapy.


Assuntos
Coagulação Sanguínea , Deficiência do Fator XII/metabolismo , Fator XIIa/metabolismo , Tromboembolia/metabolismo , Animais , Coagulação Sanguínea/efeitos dos fármacos , Coagulação Sanguínea/genética , Colágeno/administração & dosagem , Epinefrina/administração & dosagem , Fator VIIa/metabolismo , Deficiência do Fator XII/genética , Fator XIIa/genética , Hemorragia/genética , Hemorragia/metabolismo , Pulmão/metabolismo , Pulmão/patologia , Camundongos , Camundongos Mutantes , Agregação Plaquetária/efeitos dos fármacos , Agregação Plaquetária/genética , Tromboembolia/induzido quimicamente , Tromboembolia/tratamento farmacológico , Tromboembolia/patologia , Vasoconstritores/administração & dosagem
5.
Prenat Diagn ; 25(7): 574-6, 2005 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-16032767

RESUMO

Prenatal molecular genetic diagnosis for Noonan syndrome I is reported. Noonan syndrome was suspected because of large cystic hygroma colli, massive pleural effusion and ascites at 23 weeks of gestation and normal karyotype (46,XX). DNA was prepared from amnion cells and screened for mutations in the PTPN11 gene. In exon 8, a missense mutation (S285F) was found. Delivery was induced at 33 weeks of gestation because of silent cardiotocography (CTG). Despite immediate drainage of the hydrothorax, mechanical ventilation was insufficient and the child died 9 h after birth due to severe pulmonary hypoplasia. Pleural punctate was enriched for small lymphocytes and thus was characterized as chylus. Prenatal ultrasound findings in Noonan syndrome usually are unspecific and rarely lead to a diagnosis. However, with the combination of cystic hygroma, pleural effusion, ascites and normal karyotype Noonan syndrome should be considered and DNA testing for PTPN11 mutations may be appropriate. Malformations of lymphatic vessels and/or chylothorax in Noonan syndrome seem to be more frequent than usually anticipated.


Assuntos
Anormalidades Múltiplas/diagnóstico por imagem , Síndrome de Noonan/diagnóstico , Diagnóstico Pré-Natal , Anormalidades Múltiplas/embriologia , Adulto , Ascite/diagnóstico por imagem , Ascite/embriologia , Diagnóstico Diferencial , Evolução Fatal , Feminino , Humanos , Recém-Nascido , Peptídeos e Proteínas de Sinalização Intracelular/genética , Cariotipagem , Linfangioma Cístico/diagnóstico por imagem , Linfangioma Cístico/embriologia , Mutação , Síndrome de Noonan/diagnóstico por imagem , Síndrome de Noonan/embriologia , Síndrome de Noonan/patologia , Derrame Pleural/diagnóstico por imagem , Derrame Pleural/embriologia , Gravidez , Segundo Trimestre da Gravidez , Proteína Tirosina Fosfatase não Receptora Tipo 11 , Proteínas Tirosina Fosfatases/genética , Ultrassonografia
6.
Thromb Haemost ; 92(3): 503-8, 2004 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-15351846

RESUMO

To analyze the biological role of factor XII (FXII, Hageman Factor) in vivo, we generated mice deficient for FXII using a gene targeting approach on two distinct genetic backgrounds, i.e. mixed C57Bl/6J X 129X1/SvJ and inbred 129X1/SvJ. Homozygous FXII knockout (FXII(-)/(-)) mice showed no FXII plasma activity and had a markedly prolonged activated partial thromboplastin time (aPTT). In contrast, coagulation factors XI, VIII, IX, X,VII, V, II and fibrinogen did not differ between FXII(-/-) mice and their wild-type littermates. Heterozygous matings segregated according to the Mendelian inheritance indicating that FXII deficiency does not increase fetal loss. Furthermore, matings of FXII(-/-) males and FXII(-/-) females resulted in normal litter sizes demonstrating that total FXII deficiency in FXII(-/-) females does not affect pregnancy outcome. Also, gross and histological anatomy of FXII(-/-) mice was indistinguishable from that of their wild-type littermates on both genetic backgrounds. Thus it appears that deficiency of murine FXII does not cause thrombophilia or impaired fibrinolysis in vivo. These results indicate that FXII deficiency does not affect hemostasis in vivo and we anticipate that the FXII(-/-) mice will be helpful to elucidate the biological role(s) of FXII in health and disease.


Assuntos
Fator XII/genética , Fator XII/fisiologia , Camundongos Knockout , Animais , Ativação Enzimática , Feminino , Fibrinólise , Hemostasia , Humanos , Padrões de Herança , Masculino , Camundongos , Modelos Animais , Tempo de Tromboplastina Parcial , Gravidez , Resultado da Gravidez , Trombofilia
7.
Hypertens Pregnancy ; 23(1): 101-11, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15117604

RESUMO

OBJECTIVE: The aim of this study was to analyze if levels of plasma PlGF in the second half of pregnancy have predictive value for the identification of women destined to develop preeclampsia or another complication of pregnancy. MATERIAL AND METHODS: A bank of 1.543 randomly collected plasma samples (22-29 weeks of gestation) was established and PlGF concentrations were quantitated in a prospective longitudinal study in all pregnant women who developed a complication of pregnancy in late gestation (177 of 1.543) and the same number of gestational age matched pregnancies with normal outcome. RESULTS: Plasma PlGF levels in pregnant women rise steadily throughout pregnancy from the level of nonpregnant women (< 50 pg/mL) to levels exceeding 500 pg/mL after 30 weeks of gestation. Just 7.3% of pregnant women with normal outcome of pregnancy had PlGF levels of less than 200 pg/mL beyond 22 weeks of gestation (3.7% beyond 25 weeks of gestation). The rise in plasma PlGF in the second half of pregnancy was significantly attenuated in pregnancies that were complicated by preeclampsia in late gestation. Of all women who developed preeclampsia, 27.3% (12 of 44) had plasma PlGF levels below 200 pg/mL. The attenuation of the rise in plasma PlGF was not evident in other complications of pregnancy (transient hypertension, fetal retardation, pregnancy diabetes, premature contractions, proteinuria without hypertension, infections during pregnancy). CONCLUSION: The rise in plasma PlGF levels observed in normal pregnancies is significantly attenuated in pregnancies complicated by preeclampsia. Yet, due to the low sensitivity and specificity, plasma PlGF levels in the second half of pregnancy have no predictive value for the identification of individual women destined to develop preeclampsia.


Assuntos
Pré-Eclâmpsia/sangue , Proteínas da Gravidez/sangue , Adulto , Biomarcadores/sangue , Feminino , Alemanha , Síndrome HELLP/sangue , Humanos , Bem-Estar Materno , Fator de Crescimento Placentário , Gravidez , Resultado da Gravidez , Segundo Trimestre da Gravidez/sangue , Terceiro Trimestre da Gravidez/sangue , Estudos Prospectivos
8.
Acta Obstet Gynecol Scand ; 82(10): 942-7, 2003 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-12956845

RESUMO

BACKGROUND: Several etiological factors have been proposed as a cause for recurrent fetal abortions. Changes in blood coagulation during pregnancy may play an important role in the occurrence of recurrent abortions (RA). METHODS: The aim of this study was to investigate the prevalence of factor V Leiden, factor II prothrombin, and methylenetetrahydrofolate reductase (MTHFR) mutations in women with recurrent abortions (> or =2 abortions) in the German population. The mean number of abortions was 3 (range 2-8). RESULTS: Frequencies of the factor V Leiden mutation and the prothrombin G20210A mutation were equally high in the patient group compared with our control group (for factor V Leiden: 11/101 vs. 9/122; p-value: 0.348; for prothrombin G20210A: 2/101 vs. 3/122; p-value: 0.81). Moreover, in both the patient and control groups, 15 of the women were homozygous for the MTHFR C677T allele (15/101 vs. 15/122; p-value: 0.635). The occurrence of FV Leiden, FII and MTHFR mutations was not significantly increased in the patient group compared with our control group. CONCLUSION: The results of the present study reveal no relationship between these common three thrombophilic mutations and recurrent abortions for the German population, and further studies are essentially recommended on whether a thrombophilia evaluation should be performed in patients with recurrent abortions.


Assuntos
Aborto Habitual/genética , Mutação , Complicações Hematológicas na Gravidez/epidemiologia , Trombofilia/epidemiologia , Trombofilia/genética , Adulto , Estudos de Casos e Controles , Fator V/genética , Feminino , Alemanha/epidemiologia , Humanos , Incidência , Metilenotetra-Hidrofolato Redutase (NADPH2) , Oxirredutases atuantes sobre Doadores de Grupo CH-NH/genética , Gravidez , Prevalência , Protrombina/genética , População Branca/genética
9.
Fertil Steril ; 80(3): 590-4, 2003 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-12969703

RESUMO

OBJECTIVE: To evaluate factor XII deficiency in women with primary and secondary recurrent abortion. DESIGN: Prospective case-control study. SETTING: University hospital. PATIENT(S): Sixty-seven women with primary and 33 women with secondary recurrent abortion of unexplained nature and 49 healthy controls with no history of thrombotic disease or adverse pregnancy outcomes. MAIL OUTCOME MEASURE(S): Plasma factor XII activity, activated protein C resistance, factor V Leiden mutation analysis, protein C, protein S, antithrombin III, karyotyping, and anticardiolipin antibodies. RESULT(S): Ten of 67 women with primary recurrent abortion (14.9%) and 4 of 33 women (12.1%) with secondary recurrent abortion had reduced factor XII activity (<60%). These results are highly significant in the former group and showed a tendency toward significance in the latter group. All controls had normal factor XII activity. CONCLUSION(S): Factor XII deficiency is strongly associated with primary recurrent abortion, and women with secondary recurrent abortion show a tendency toward factor XII deficiency.


Assuntos
Aborto Habitual/complicações , Deficiência do Fator XII/complicações , Deficiência do Fator XII/epidemiologia , Resistência à Proteína C Ativada/genética , Adulto , Anticorpos Antifosfolipídeos/sangue , Transtornos da Coagulação Sanguínea/complicações , Estudos de Casos e Controles , Análise Citogenética , Fator V/genética , Deficiência do Fator XII/genética , Deficiência do Fator XII/fisiopatologia , Feminino , Humanos , Prevalência , Estudos Prospectivos , Útero/anormalidades
10.
Arch Gynecol Obstet ; 268(1): 52-6, 2003 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12673477

RESUMO

Oligo- and polyhydramnios could be observed in 1%-7% of all pregnancies and are associated with an increased risk of fetal anomalies. We evaluated the fetal outcomes of 840 pregnancies with oligo- and polyhydramnios on the basis of ultrasonographic findings (oligohydramnios: single deepest pocket <2 cm, polyhydramnios: single deepest pocket >8 cm) between 12 and 42 weeks of gestation. We observed 734 pregnancies (752 fetuses) with oligohydramnios and 106 pregnancies (108 fetuses) with polyhydramnios. Of the 752 fetuses with oligohydramnios, 81% survived and 19% died in utero. Among the 108 fetuses of pregnancies with polyhydramnios, 72% of the babies survived and 28% died in utero. In polyhydramnios, 48% (52 of 108) of the fetuses had severe malformations, which is significant compared to the rate of 11.8% (89 of 752) of fetal malformations in oligohydramnios ( P-value<0.001). Oligohydramnios is predominantly associated with malformations of the urinary tract, whereas polyhydramnios is associated with anomalies of the gastrointestinal tract. In conclusion, measurement of single deepest pocket is a valuable screening method to evaluate pregnancies showing the complications of oligo- and polyhydramnios. Pregnancies with severe polyhydramnios have a poorer outcome and fetuses have a significantly higher risk of congenital malformations compared to pregnancies with oligohydramnios.


Assuntos
Feto/anormalidades , Oligo-Hidrâmnio/complicações , Poli-Hidrâmnios/complicações , Anormalidades Congênitas/diagnóstico por imagem , Anormalidades Congênitas/epidemiologia , Anormalidades Congênitas/etiologia , Feminino , Morte Fetal/etiologia , Humanos , Incidência , Gravidez , Fatores de Risco , Ultrassonografia Pré-Natal
11.
Pathophysiol Haemost Thromb ; 33(3): 134-7, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-15170393

RESUMO

Thrombophilic disorders and hypofibrinolysis were demonstrated to be risk factors in a majority of women with recurrent pregnancy loss (RPL) and infertility. We investigated the association of FV G1691A mutation, F II G20210A gene polymorphism (PM), 4G/5G PAI-1 and Alu I/D tPA PM in 32 women with infertility and 49 women with at least 2 unexplained early abortions. FV Leiden mutation was significantly more common in women with RPL (10%, p = 0.02) and infertility (19%, p = 0.0005) compared with controls (2%). PAI-1 4G PM and t-PA Alu I PM, alone or in combination, were not associated with RPL or infertility. 9/49 women with RPL showed coagulation disorders with heterozygous FV Leiden mutation (5), FXII (1), protein C (1) or protein S (2) deficiency. However, due to the small number of patients studied, no definite conclusion can be drawn.


Assuntos
Aborto Habitual/sangue , Fatores de Coagulação Sanguínea/genética , Ativadores de Plasminogênio/genética , Polimorfismo Genético , Aborto Habitual/etiologia , Aborto Habitual/genética , Adulto , Estudos de Casos e Controles , Estudos Transversais , Fator V , Feminino , Frequência do Gene , Humanos , Infertilidade Feminina/sangue , Infertilidade Feminina/etiologia , Infertilidade Feminina/genética , Inibidor 1 de Ativador de Plasminogênio/genética , Gravidez , Complicações Hematológicas na Gravidez , Estudos Prospectivos , Protrombina/genética , Trombofilia/complicações
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...